Santaris Pharma A/s

Roche Innovation Center Copenhagen A/s

Exiqon A/s

Novo Nordisk A/s

Dartmouth College

Novozymes Biotech, Inc

Other

Novozymes A/s

Novozymes, Inc.

Novo Nordisk Biotech, Inc.

Koebenhavns Universitet (university of Copenhagen)

Univ. of Copenhagen

Novo Nordisk of Biotech, Inc.

Sakari Kauppinen

Susanna Obad

Joacim Elmén

Morten Lindow

Markus Heidenblad

Debbie Sue Yaver

Torben Halkier

Lene Venke Kofod

Ethan Dmitrovsky

Søren Morgenthaler Echwald

Sarah Freemantle

Peter Stein Nielsen

Kimberley M Brown

Charles Cole

Niels Abrahamsen

Elisabeth S Hildebrandt-Eriksen

Mette Christensen

Mads Bak

Xi Liu

Phil Kearney

Michael W Rey

Randy M Berka

Lene Nonboe Andersen

Stephan Christgau

Hans Peter Heldt-Hansen

Ib Groth Clausen

Jeffrey R Shuster

Peter Bjarke Olsen

Lars Kongsbak

Peter Mouritzen

Martin Munk

Nana Jacobsen

Mikkel Nørholm

Henrik Dalbo Slashedge

Gitte Budolfsen

Peter Hagedorn

Lorenzo Sempere

Jesper Wengel

Andreas Petri

Jesper Worm

Thomas Sandal

Henrik Dalboege

Jan Stenvang

Lorenzo F Sempere

Niels Tolstrup

Robert Eldon Lanford

Carsten Alsbo

Daniel C Jeffares

Tobias Mourier

Søren Mørk

Peter Arctander

Niels Tommerup

Henrik Vissing

Elisabeth Hildebrandt-Eriksen

Robert Lanford

The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.

Micromirs

MICROMIRs

The invention features improved nucleic acids and methods for expression profiling of mRNAs, identifying and profiling of particular mRNA splice variants, and detecting mutations, deletions, or duplications of particular exons or other splice variants, e.g., alterations associated with a disease such as cancer, in a nucleic acid sample, e.g., a biological sample or a patient sample.

Oligonucleotides useful for detecting and analyzing nucleic acids of interest

The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogs into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.

Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides

The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.

MicroRNA biomarkers for human breast and lung cancer

The present invention provides compositions and methods of treatment of HCV infected subjects that are not sensitive to interferon treatment. Further, compositions and methods are provided for prevention of organ transplant rejection. The compositions of the invention comprise an anti microRNA-122 oligonucleotide, and are made for administration to a primate.

Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon

MicromiRs

The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 26 nucleobases which are complementary to human microRNAs selected from the group consisting of miR19b, miR21, miR122a, miR155 and miR375. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides results in highly effective anti-microRNA molecules which appear to function via the formation of almost irreversible duplexes with the miRNA target, rather than RNA cleavage based mechanisms, such as mechanisms associated with RNaseH or RISC.

Antisense oligonucleotides for inhibition of microRNA-21

The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.

Micro-RNA mediated modulation of colony stimulating factors

The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered to a primate. Therefore, the present invention relate to pharmaceutical compositions and methods for treatment of primates, including humans wherein the compositions are administered with a long time interval.

Pharmaceutical compositions for treatment of MicroRNA related diseases

The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids.

Methods for quantification of microRNAs and small interfering RNAs

Pharmaceutical compositions for treatment of microRNA related diseases

MicroRNAs

Growing community of inventors

Smørum, Denmark

Sakari Kauppinen